A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models

(2012) David A. Proia et al.   INVESTIGATIONAL NEW DRUGS

The network interaction of the human cytosolic 90kDa heat shock protein Hsp90: A target for cancer therapeutics

(2012) Viviane C.H. da Silva et al.   Journal of Proteomics

Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats.

(2012) D. Zhou et al.   MOLECULAR CANCER THERAPEUTICS

HSP90 as a platform for the assembly of more effective cancer chemotherapy

(2011) Luke Whitesell et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

(2011) A. Rajan et al.   CLINICAL CANCER RESEARCH

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

(2011) Simon Pacey et al.   CLINICAL CANCER RESEARCH

Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010

(2011) Samir Messaoudi et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

(2011) W. Ying et al.   MOLECULAR CANCER THERAPEUTICS

Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

(2011) David A. Proia et al.   PLoS One

An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors

(2010) Naveen Dakappagari et al.   BIOMARKERS

Geldanamycin and its analog induce cytotoxicity in cultured human retinal pigment epithelial cells

(2010) Wen-Chuan Wu et al.   EXPERIMENTAL EYE RESEARCH

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

(2010) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Pharmacokinetic and Pharmacodynamic Study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an Inhibitor of Heat-Shock Protein 90, in Patients With Advanced Solid Tumors

(2010) Ramesh K. Ramanathan et al.   JOURNAL OF CLINICAL ONCOLOGY

EGF signaling activates proliferation and blocks apoptosis of mouse and human intestinal stem/progenitor cells in long-term monolayer cell culture

(2010) Atsushi Suzuki et al.   LABORATORY INVESTIGATION

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

(2010) J E Lancet et al.   LEUKEMIA

Geldanamycin inhibits TGF-β signaling through induction of Hsp70

(2009) Chang-Hyun Yun et al.   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Hsp90 and co-chaperones twist the functions of diverse client proteins

(2009) Abbey Zuehlke et al.   BIOPOLYMERS

Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation

(2008) B. Dewaele et al.   CLINICAL CANCER RESEARCH

Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells

(2008) Tuomas Ryhänen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY